By Lauran Neergaard
Survivors of COVID-19 are donating their blood plasma in droves in hopes it helps other patients recover from the coronavirus. And while the jury’s still out, now scientists are testing if the donations might also prevent infection in the first place.
Thousands of coronavirus patients in hospitals around the world have been treated with so-called convalescent plasma — including more than 20,000 in the U.S. — with little solid evidence so far that it makes a difference. One recent study from China was unclear while another from New York offered a hint of benefit.
“We have glimmers of hope,” said Dr. Shmuel Shoham of Johns Hopkins University.
With more rigorous testing of plasma treatment underway, Shoham is launching a nationwide study asking the next logical question: Could giving survivors plasma right after a high-risk exposure to the virus stave off illness?
To tell, researchers at Hopkins and 15 other sites will recruit health workers, spouses of the sick and residents of nursing homes where someone just fell ill and “they’re trying to nip it in the bud,” Shoham said.
It’s a strict study: The 150 volunteers will be randomly assigned to get either plasma from COVID-19 survivors that contains coronavirus-fighting antibodies or regular plasma, like is used daily in hospitals, that was frozen prior to the pandemic. Scientists will track if there’s a difference in who gets sick.
It if works, survivor plasma could have important ramifications until a vaccine arrives — raising the prospect of possibly protecting high-risk people with temporary immune-boosting infusions every so often.
“They’re a paramedic, they’re a police officer, they’re a poultry industry worker, they’re a submarine naval officer,” Shoham ticked off. “Can we blanket protect them?”
The new coronavirus has infected more than 7 million people worldwide and killed more than 400,000, according to official tallies believed to be an underestimate. With no good treatments yet, researchers are frantically studying everything from drugs that tackle other viruses to survivor plasma — a century-old remedy used to fight infection before modern medicines came along.
The historical evidence is sketchy, but convalescent plasma's most famous use was during the 1918 flu pandemic, and reports suggest that recipients were less likely to die. Doctors still dust off the approach to tackle surprise outbreaks, like SARS, a cousin of COVID-19, in 2002, and the 2014 Ebola epidemic in West Africa, but even those recent uses lacked rigorous research.
When the body encounters a new germ, it makes proteins called antibodies that are specially targeted to fight the infection. The antibodies float in plasma — the yellowish, liquid part of blood.
Because it takes a few weeks for antibodies to form, the hope is that transfusing someone else’s antibodies could help patients fight the virus before their own immune system kicks in. One donation is typically divided into two or three treatments.
And as more people survive COVID-19, there are increasing calls for them to donate plasma so there's enough of a stockpile if it pans out. In addition to traditional infusions, donations can be combined into a high-dose product. Manufacturer Grifols is producing doses of that “hyperimmune globulin" for a study expected to start next month.
Convalescent plasma seems safe to use, Dr. Michael Joyner of the Mayo Clinic reported last month. His team tracked the first 5,000 plasma recipients in a Food and Drug Administration-sponsored program that helps hospitals use the experimental treatment, and found few serious side effects.
Does it help recovery? A clue comes from the first 39 patients treated at New York’s Mount Sinai Hospital. Researchers compared each plasma recipient to four other COVID-19 patients who didn't get plasma but were the same age, just as sick and being given the same amount of oxygen. People who received plasma before needing a ventilator were less likely to die than non-plasma recipients, said Dr. Sean Liu, the study’s lead author.
“We really tried to target patients who were early in their course, preferably within the first one to two weeks of their disease,” Liu said.
“Being a doctor during this time, you just feel helpless,” Liu added, stressing that more rigorous study was needed but he was glad to have tried this first-step research. “Watching people die is, it's heartbreaking. It's scary and it's heartbreaking.”
But the results of the first strictly controlled study were disappointing. Hospitals in the hard-hit Chinese city of Wuhan were comparing severely ill patients randomly assigned to receive plasma or regular care, but ran out of new patients when the virus waned.
With only half of the 200 planned patients enrolled, more plasma recipients survived but researchers couldn't tell if it was a real difference or coincidence, according to a report in the Journal of the American Medical Association last week.
The real proof will come from ongoing, strict studies that compare patients assigned to get either survivor plasma or a dummy treatment.
Further complicating the search for answers, COVID-19 survivors harbor widely varying levels of antibodies. And while researchers want to use what Hopkins’ Shoham calls “the high-octane stuff,” no one knows the best dose to test.
“About 20% of recovered patients and donors have very strong immunity,” estimated Dr. Michele Donato of Hackensack University Medical Center, who is studying how long they retain that level of protection.
Those are the people researchers want to become repeat donors.
“It’s, I think, our job as humans to step forward and help in society,” said Aubrie Cresswell, 24, of Bear, Delaware, who has donated three times and counting.
One donation was shipped to a hospitalized friend of a friend, and “it brought me to tears. I was like, overwhelmed with it just because the family was really thankful.”
___
AP video journalist Kathy Young contributed to this report.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
